0.00Open0.00Pre Close0 Volume0 Open Interest84.00Strike Price0.00Turnover4938.38%IV-7.78%PremiumNov 22, 2024Expiry Date6.06Intrinsic Value100Multiplier-3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9312Delta0.0194Gamma--Leverage Ratio-330.7581Theta0.0000Rho0.00Eff Leverage0.0002Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet